0.00Open0.00Pre Close0 Volume0 Open Interest6.00Strike Price0.00Turnover9013.19%IV63.93%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.4658Delta0.1191Gamma4.88Leverage Ratio-18.1665Theta0.0000Rho2.27Eff Leverage0.0001Vega
VistaGen Therapeutics Stock Discussion
Vistagen Broadens Ph80 Global Intellectual Property Portfolio With New Patents for the Treatment of Migraine
VistaGen Therapeutics GAAP EPS of -$1.52 misses by $1.16, revenue of $1.06M beats by $0.86M
Jun. 11, 2024 4:23 PM ETVistagen Therapeutics, Inc. (VTGN) StockBy: Mary Christine Joy, SA News Editor
VistaGen Therapeutics press release (NASDAQ:VTGN): Q4 GAAP EPS of -$1.52 misses by $1.16.
Revenue of $1.06M (vs. -$0.23M last year) beats by $0.86M.
Shares +0.8%.
Registration-directed fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder...
Vistagen Reports FY24 Net Loss Of $(29.4)M Vs $(59.2)M Last Year
238k shares bought 5.4
No comment yet